Medherant said today that it was awarded a Medicines Manufacturing Grant from Innovate UK to support the manufacturing of transdermal drug-delivery patches.
The company plans to expand its pilot-scale GMP manufacturing program, which is designed to make patches formulated with its Tepi patch tech for clinical trials.
Medherant touts its Tepi technology as enabling the development of transdermal patch products with better adhesion and more efficient drug delivery through the skin compared to traditional patches. The company’s first product, an ibuprofen patch, is involved in a Phase I trial with initial results slated for the fourth quarter.
The company develops transdermal patches and then out-licenses them to established pharma companies for commercialization, according to Medherant.
The UK-based company reported that its pilot-scale patch manufacturing plant has successfully produced non-GMP patches of the ibuprofen Tepi patch. Medherant has also reportedly made Tepi patches for other companies that are interested in evaluating Medherant’s technology for their own drugs.
The company noted that it can create candidate patch formulations for third-party groups in just 2-3 months.
